select a format

Single User License
USD 2000 INR 129840
Site License
USD 4000 INR 259680
Corporate User License
USD 6000 INR 389520

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Focal Segmental Glomerulosclerosis (FSGS)-Pipeline Review, H2 2016

Focal Segmental Glomerulosclerosis (FSGS)-Pipeline Review, H2 2016


  • Products Id :- GMDHC8916IDB
  • |
  • Pages: 58
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Focal Segmental Glomerulosclerosis (FSGS)-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Focal Segmental Glomerulosclerosis-Pipeline Review, H2 2016, provides an overview of the Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Focal Segmental glomerulosclerosis is a rare disease that attacks the kidney's filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and even failure. Symptoms include proteinuria, edema, high cholesterol, high blood pressure and poor appetite. Risk factors include infection, obesity, sickle cell disease and reflux nephropathy. Treatment includes antibiotics, vitamin D supplements, and immunosuppressive drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Focal Segmental Glomerulosclerosis-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Focal Segmental Glomerulosclerosis (FSGS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Focal Segmental Glomerulosclerosis (FSGS) Overview 6

Therapeutics Development 7

Pipeline Products for Focal Segmental Glomerulosclerosis (FSGS)-Overview 7

Pipeline Products for Focal Segmental Glomerulosclerosis (FSGS)-Comparative Analysis 8

Focal Segmental Glomerulosclerosis (FSGS)-Therapeutics under Development by Companies 9

Focal Segmental Glomerulosclerosis (FSGS)-Therapeutics under Investigation by Universities/Institutes 10

Focal Segmental Glomerulosclerosis (FSGS)-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Focal Segmental Glomerulosclerosis (FSGS)-Products under Development by Companies 13

Focal Segmental Glomerulosclerosis (FSGS)-Products under Investigation by Universities/Institutes 14

Focal Segmental Glomerulosclerosis (FSGS)-Companies Involved in Therapeutics Development 15

Complexa Inc 15

Dimerix Bioscience Pty Ltd 16

GlaxoSmithKline Plc 17

Retrophin Inc 18

Shire Plc 19

Variant Pharmaceuticals Inc 20

Focal Segmental Glomerulosclerosis (FSGS)-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Combination Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 30

(irbesartan + propagermanium)-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

CXA-10-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

losmapimod-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

SHP-627-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

sparsentan-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

TM-5484-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

VAR-200-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Focal Segmental Glomerulosclerosis (FSGS)-Dormant Projects 44

Focal Segmental Glomerulosclerosis (FSGS)-Discontinued Products 45

Focal Segmental Glomerulosclerosis (FSGS)-Product Development Milestones 46

Featured News & Press Releases 46

Nov 30, 2016: World Renowned Experts Join Variant Pharmaceuticals' Scientific Advisory Board 46

Nov 21, 2016: Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016 47

Nov 19, 2016: Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016 48

Oct 21, 2016: Retrophin to Present Additional Data from Phase 2 DUET Study of Sparsentan in Late-Breaking Oral Session at ASN Kidney Week 2016 49

Sep 07, 2016: Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis 51

Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA 51

Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis 52

Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease 53

Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis 54

Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan 54

Feb 25, 2013: Ligand Receives $1.4m Milestone Payment From Retrophin 55

Jan 09, 2013: Ligand Receives Equity Milestone Payment From Retrophin 55

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Figures

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS), H2 2016 7

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS)-Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Targets, H2 2016 23

Number of Products by Stage and Targets, H2 2016 23

Number of Products by Mechanism of Actions, H2 2016 25

Number of Products by Stage and Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 29

List of Tables

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS), H2 2016 7

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS)-Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Focal Segmental Glomerulosclerosis (FSGS)-Pipeline by Complexa Inc, H2 2016 15

Focal Segmental Glomerulosclerosis (FSGS)-Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 16

Focal Segmental Glomerulosclerosis (FSGS)-Pipeline by GlaxoSmithKline Plc, H2 2016 17

Focal Segmental Glomerulosclerosis (FSGS)-Pipeline by Retrophin Inc, H2 2016 18

Focal Segmental Glomerulosclerosis (FSGS)-Pipeline by Shire Plc, H2 2016 19

Focal Segmental Glomerulosclerosis (FSGS)-Pipeline by Variant Pharmaceuticals Inc, H2 2016 20

Assessment by Monotherapy Products, H2 2016 21

Assessment by Combination Products, H2 2016 22

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 29

Focal Segmental Glomerulosclerosis (FSGS)-Dormant Projects, H2 2016 44

Focal Segmental Glomerulosclerosis (FSGS)-Discontinued Products, H2 2016 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Complexa Inc, Dimerix Bioscience Pty Ltd, GlaxoSmithKline Plc, Retrophin Inc, Shire Plc, Variant Pharmaceuticals Inc

Focal Segmental Glomerulosclerosis (FSGS) Therapeutic Products under Development, Key Players in Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, Focal Segmental Glomerulosclerosis (FSGS) Pipeline Overview, Focal Segmental Glomerulosclerosis (FSGS) Pipeline, Focal Segmental Glomerulosclerosis (FSGS) Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com